JP2020500525A - 対合が改善されたt細胞受容体t細胞 - Google Patents
対合が改善されたt細胞受容体t細胞 Download PDFInfo
- Publication number
- JP2020500525A JP2020500525A JP2019529260A JP2019529260A JP2020500525A JP 2020500525 A JP2020500525 A JP 2020500525A JP 2019529260 A JP2019529260 A JP 2019529260A JP 2019529260 A JP2019529260 A JP 2019529260A JP 2020500525 A JP2020500525 A JP 2020500525A
- Authority
- JP
- Japan
- Prior art keywords
- tcr
- chain
- modified
- cell receptor
- βr44d
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091008874 T cell receptors Proteins 0.000 title claims abstract description 182
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title claims abstract description 179
- 210000001744 T-lymphocyte Anatomy 0.000 title claims description 71
- 150000001413 amino acids Chemical class 0.000 claims abstract description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 19
- 239000000833 heterodimer Substances 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims description 36
- 239000000427 antigen Substances 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 238000006467 substitution reaction Methods 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- 238000002659 cell therapy Methods 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 230000001613 neoplastic effect Effects 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 230000002463 transducing effect Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000013600 plasmid vector Substances 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 33
- 108090000765 processed proteins & peptides Proteins 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 20
- 230000035772 mutation Effects 0.000 description 18
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 17
- 238000013459 approach Methods 0.000 description 16
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 16
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 10
- 239000013598 vector Substances 0.000 description 9
- 102000011786 HLA-A Antigens Human genes 0.000 description 8
- 108010075704 HLA-A Antigens Proteins 0.000 description 8
- 101000606220 Homo sapiens T cell receptor beta variable 6-5 Proteins 0.000 description 8
- 102100039786 T cell receptor beta variable 6-5 Human genes 0.000 description 8
- 101000794366 Homo sapiens T cell receptor alpha variable 8-6 Proteins 0.000 description 7
- 102100030186 T cell receptor alpha variable 8-6 Human genes 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 108091033409 CRISPR Proteins 0.000 description 6
- 238000010354 CRISPR gene editing Methods 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 241000703392 Tribec virus Species 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 101000794371 Homo sapiens T cell receptor alpha variable 5 Proteins 0.000 description 4
- 101000939858 Homo sapiens T cell receptor beta variable 12-4 Proteins 0.000 description 4
- 102100030178 T cell receptor alpha variable 5 Human genes 0.000 description 4
- 102100029697 T cell receptor beta variable 12-4 Human genes 0.000 description 4
- 238000005094 computer simulation Methods 0.000 description 4
- -1 cysteine amino acid Chemical class 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 238000010362 genome editing Methods 0.000 description 4
- 238000002708 random mutagenesis Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000002741 site-directed mutagenesis Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102220632799 Immunoglobulin heavy variable 1-69_R11A_mutation Human genes 0.000 description 3
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 3
- 238000010459 TALEN Methods 0.000 description 3
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- 102220473068 Chemerin-like receptor 2_R17Q_mutation Human genes 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 240000007019 Oxalis corniculata Species 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- 238000011467 adoptive cell therapy Methods 0.000 description 2
- 150000001371 alpha-amino acids Chemical class 0.000 description 2
- 235000008206 alpha-amino acids Nutrition 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000009126 molecular therapy Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000008682 Argonaute Proteins Human genes 0.000 description 1
- 108010088141 Argonaute Proteins Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940123611 Genome editing Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000772111 Homo sapiens T cell receptor alpha variable 2 Proteins 0.000 description 1
- 101000772105 Homo sapiens T cell receptor alpha variable 24 Proteins 0.000 description 1
- 101000794419 Homo sapiens T cell receptor alpha variable 40 Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 101100096028 Mus musculus Smok1 gene Proteins 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100029486 T cell receptor alpha variable 2 Human genes 0.000 description 1
- 102100029484 T cell receptor alpha variable 24 Human genes 0.000 description 1
- 102100030197 T cell receptor alpha variable 40 Human genes 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102220612309 T-cell surface glycoprotein CD4_S85R_mutation Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 description 1
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000012910 preclinical development Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 102220005008 rs267606870 Human genes 0.000 description 1
- 102200083530 rs34382405 Human genes 0.000 description 1
- 102220033174 rs62642581 Human genes 0.000 description 1
- 102220067424 rs757120802 Human genes 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Abstract
Description
1.マウス化TCR:このアプロ−チでは、ヒトTCRαおよびβ定常鎖が、対応するマウスドメインによって置換される。ヒトおよびマウスのTCR−Cドメインは高度な相同性を示すが、わずかな相違が、TCR/CD3相互作用の安定性、したがってTCR表面発現レベルに影響を及ぼす。
2.システイン修飾TCR:このアプロ−チは、構造的に好ましい位置にシステインアミノ酸を導入し、それ故、さらなるジスルフィド架橋の形成を可能にして、2つのTCR鎖間の正しい対合を促進する。TCRα定常鎖におけるT48CおよびTCRβ定常鎖におけるS57Cなどの部位特異的変異は、2つの鎖間結合によって連結されたTCRヘテロ二量体をもたらした(すなわち導入されたジスルフィド架橋と内在性膜貫通ジスルフィド架橋(α定常ドメインの95位およびβ定常ドメインの131位)。
3.ドメイン交換:定常ドメインを腫瘍特異的T細胞受容体のα鎖とβ鎖との間で交換し、ドメイン交換(ds)TCRを作り出す。正しく対合した場合、これらのdsTCR鎖は、CD3タンパク質を動員してT細胞表面上で発現して標的抗原との係合時に機能的T細胞応答を媒介するのに必要である、全てのドメインを保持する。対照的に、1本のdsTCR鎖と1本の野生型TCR鎖を含有する誤対合TCRは、CD3の動員、搬出、およびシグナル伝達に必要な重要なドメインを欠いており、したがって有害な自己免疫を媒介できない。
4.排他的TCRヘテロ二量体:このアプロ−チでは、立体力と静電気力を利用してTCRαおよびβ導入遺伝子間の正しい対合を容易にし、同時に、外在性および内在性のTCRα鎖およびβ鎖間のペアリングを阻害する。一例では、必要な静電荷の変化を得るために、部位特異的変異を用いてS85Rがα定常ドメインに、R88Gがβ定常ドメインに導入され、したがって相互の「ノブ−イン−ホ−ル」配置が生成し、これは二次および三次構造を最小限に歪ませるとされる。
5.各TCR鎖がCD3ζ分子に融合している、キメラTCR−CD3ζ鎖の使用。
6.規定のTCRのVαが、可撓性のペプチドリンカ−を使用してβ鎖に融合している、一本鎖TCRの使用。
7.内在性TCRの発現をノックダウンするためのshRNA配列またはジンクフィンガ−ヌクレア−ゼの使用。
X1X2LEHVVRX3
式中、X1はアミノ酸KおよびYから選択され、X2はアミノ酸V、L、およびAから選択され、X3はV、L、A、およびIから選択される。
αQ44D/βQ44R;αQ44R/βQ44D;αQ44E/βQ44K;αQ44K/βQ44E;αQ44D/βQ44K;αQ44K/βQ44D;αQ44E/βQ44R;αQ44R/βQ44E;αQ44L/βQ44W;αQ44W/βQ44L;αQ44V/βQ44W;およびαQ44W/βQ44V;
αW44D/βQ44R;αW44R/βQ44D;αW44E/βQ44K;αW44K/βQ44E;αW44D/βQ44K;αW44K/βQ44D;αW44E/βQ44R;αW44R/βQ44E;αW44L/βQ44W;αW44/βQ44L;αW44V/βQ44W;およびαW44/βQ44V;
αH44D/βQ44R;αH44R/βQ44D;αH44E/βQ44K;αH44K/βQ44E;αH44D/βQ44K;αH44K/βQ44D;αH44E/βQ44R;αH44R/βQ44E;αH44L/βQ44W;αH44W/βQ44L;αH44V/βQ44W;およびαH44W/βQ44V;
αK44D/βQ44R;αK44R/βQ44D;αK44E/βQ44K;αK44/βQ44E;αK44D/βQ44K;αK44/βQ44D;αK44E/βQ44R;αK44R/βQ44E;αK44L/βQ44W;αK44W/βQ44L;αK44V/βQ44W;およびαK44W/βQ44V;
αE44D/βQ44R;αE44R/βQ44D;αE44/βQ44K;αE44K/βQ44E;αE44D/βQ44K;αE44K/βQ44D;αE44/βQ44R;αE44R/βQ44E;αE44L/βQ44W;αE44W/βQ44L;αE44V/βQ44W;およびαE44W/βQ44V;
αQ44D/βR44;αQ44R/βR44D;αQ44E/βR44K;αQ44K/βR44E;αQ44D/βR44K;αQ44K/βR44D;αQ44E/βR44;αQ44R/βR44E;αQ44L/βR44W;αQ44W/βR44L;αQ44V/βR44W;およびαQ44W/βR44V;
αW44D/βR44;αW44R/βR44D;αW44E/βR44K;αW44K/βR44E;αW44D/βR44K;αW44K/βR44D;αW44E/βR44;αW44R/βR44E;αW44L/βR44W;αW44/βR44L;αW44V/βR44W;およびαW44/βR44V;
αH44D/βR44;αH44R/βR44D;αH44E/βR44K;αH44K/βR44E;αH44D/βR44K;αH44K/βR44D;αH44E/βR44;αH44R/βR44E;αH44L/βR44W;αH44W/βR44L;αH44V/βR44W;およびαH44W/βR44V;
αK44D/βR44;αK44R/βR44D;αK44E/βR44K;αK44/βR44E;αK44D/βR44K;αK44/βR44D;αK44E/βR44;αK44R/βR44E;αK44L/βR44W;αK44W/βR44L;αK44V/βR44W;およびαK44W/βR44V;
αE44D/βR44;αE44R/βR44D;αE44/βR44K;αE44K/βR44E;αE44D/βR44K;αE44K/βR44D;αE44R/βR44E;αE44L/βR44W;αE44W/βR44L;αE44V/βR44W;およびαE44W/βR44V。
a)修飾α鎖は、可変ドメインの44位にQまたは任意のその他の適切なアミノ酸を有する非修飾β鎖と比較して、好ましくは修飾β鎖と対合し、および/または
b)修飾β鎖は、可変ドメイン中の44位にQまたは任意のその他の適切なアミノ酸を有する非修飾α鎖と比較して、好ましくは修飾α鎖と対合する。
前記1つまたは複数のコ−ド核酸分子に作動可能に連結されるプロモ−タ−、および/または
前記1つまたは複数のコ−ド核酸分子に作動可能に連結されるシグナル配列
の少なくとも1つをさらに含んでなる。
対象からT細胞を得るステップと、
前記T細胞を本発明による1つまたは複数の核酸分子で、または本発明によるプラスミドもしくはベクタ−で、形質導入または形質移入するステップと
を含んでなる。
1G4 TCRの可変ドメイン(pdb ID:2BNR(Chen et al.,2005))を目視検査することによって、本発明者らは、立体的および/または電荷の対称性を破る一方で、潜在的に高レベルの分子接触(極性または無極性)を維持するであろう変異の対をα44/β44モチ−フについて手動で選択した。変異対は、(i)対の総電荷がゼロであり、(ii)2つのアミノ酸が、潜在的に良好な形状相補性を示しおよび/または水素結合および/または塩橋を形成し、(iii)2つのアミノ酸が異なる分子量を有する(すなわち1つの大型アミノ酸と1つの小型アミノ酸)ように選択した。Discovery Studioソフトウェア(Dassault Systemes,BIOVIA,2017)を用いて、操作された位置がTCRのαβ対合に及ぼす影響をさらに調べた。Spassov et al.(Spassov and Yan,2013)によって記載されたアルゴリズムを用いて変異エネルギ−を計算し、抗体のコンピュ−タシミュレ−ションによる設計を行った。変異エネルギ−は、野生型モチ−フαQ44/βQ44との比較で、変異の効果を反映すると予測された。本発明者らは、二重変異体ならびに野生型鎖と対合した各単一変異体を試験し、
−二重変異体の場合、変異エネルギ−は中立でありまたは安定化することが予測され、
−野生型鎖と対合する単一変異体の場合、変異エネルギ−は2つの側面の少なくとも1つで不安定化することが予測された。
DavisMM, Bjorkman PJ T−cellantigen receptor genes and T−cellrecognition. (1988). 334(6181), 395〜402.
ColeDK et al. Germ line−governedrecognition of a cancer epitope by an immunodominant human T−cell receptor. (2009). 284(40),27281〜27289.
LiH et al. Structure−functionstudies of T−cellreceptor−superantigeninteractions. (1998). 163, 177〜186.
BurrowsSR Hard wiring of T cell receptor specificity for themajor histocompatibility complex is underpinned by TCR adaptability. (2010). 107(23),10608〜10613.
Roomp K Domingues FS (2011). Predicting interactions between T−cell receptors and MHC−peptidecomplexes. Mol Immunol 48:553〜562.
Rosenberg SA et al. (1988). Use of tumor−infiltrating lymphocytes and interleukin− 2in the immunotherapy of patients with metastatic melanoma. A preliminaryreport. N Engl J Med 319:1676〜1680.
Shao H et al. TCR mispairing in genetically modified T cells wasdetected by fluorescence resonance energy transfer. (2010). 37(8),3951〜3956.
LefrancMP et al. IMGT unique numbering for immunoglobulin and T cell receptor variabledomains and Ig superfamily V−likedomains. Dev. Comp. Immunol. (2003) 27, 55−77
LefrancMP et al. The T cell receptor facts book. (2001)
Bendle GM et al. Preclinical development of T cellreceptor gene therapy. Curr. Opin. Immunol. (2009). 21, 209〜214
PogulisRJ, Pease LR. A retroviral vector that directs simultaneous expression of α andβ T cell receptor genes. Hum Gene Ther. (1998) Oct 10;9(15): 2299−304.
Zhong S etal. Retroviral Transduction of T−cell Receptors in Mouse T−cells J Vis Exp. (2010); (44): 2307
WälchliS et al. A Practical Approach to T−Cell Receptor Cloning and Expression. PLOS ONE (2011)6(11): e27930
O’SheaEK et al. Peptide “Velcro”: design of a heterodimeric coiled coil. (1993). 3(10),658〜667.
ChangHC et al. A general method for facilitating heterodimeric pairing between twoproteins: application to expression of alpha and beta T−cellreceptor extracellular segments. (1994). 91(24), 11408〜11412.
VarrialeS et al. An evolutionary conserved motif is responsible for immunoglobulinheavy chain packing in the B cell membrane. (2010).
GoversC et al. T cell receptor gene therapy: strategies for optimizing transgenic TCRpairing. Trends Mol Med. (2010) Feb;16(2):77−87
LøsetGA et al., Phage Display Engineered T Cell Receptors as Tools for the Study ofTumor Peptide-MHC Interactions. Front Oncol (2014); 4: 378.
HughesRA et al. Gene synthesis: methods and applications. Methods Enzymol. (2011);498: 277−309
Labrou NE.Random mutagenesis methods for in vitro directed enzyme evolution. Curr ProteinPept Sci. (2010) Feb;11(1):91−100.
Trehan A etal. REPLACR−mutagenesis, a one−step method for site−direc Scientific Reports (2016) 6, Article number:19121
Maeder ML& Gersbach CA. Genome−editingTechnologies for Gene and Cell Therapy. Molecular Therapy (2016); 24 3,430〜446.
Verhoeyen E et al. Lentiviral vector gene transferinto human T cells. Methods Mol Biol. 2009;506:97−114
Huang X et al. Sleeping Beauty Transposon−mediated Engineering of Human Primary T Cells forTherapy of CD19+ Lymphoid Malignancies. Molecular Therapy (2008); 16 3,580〜589.
Kim TK & Eberwine JH. Mammalian cell transfection:the present and the future. Anal Bioanal Chem. 2010 Aug; 397(8): 3173〜3178.
Chen, JL et al. (2005). Structural and kinetic basisfor heightened immunogenicity of T cell vaccines. The Journal of ExperimentalMedicine, 201(8), 1243〜1255.
Pettersen EF et al. (2004). UCSF Chimera−−a visualization system for exploratory research andanalysis. Journal of Computational Chemistry, 25(13), 1605〜1612.
Spassov VZ & Yan L (2013). pH−selective mutagenesis of protein−protein interfaces: in silico design of therapeutic antibodieswith prolonged half−life.Proteins: Structure, Function, and Bioinformatics, 81(4), 704〜714.
Cohen CJ et al. Enhanced antitumor activity of murine−human hybrid T−cellreceptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3stability. Cancer Res. 2006 Sep 1;66(17):8878−86.
Cohen CJ et al. Enhanced antitumor activity of T cellsengineered to express T−cellreceptors with a second disulfide bond. Cancer Res. 2007 Apr 15;67(8):3898−903.
Voss RH et al. Molecular design of the Calphabetainterface favors specific pairing of introduced TCRalphabeta in human T cells.J Immunol. 2008 Jan 1;180(1):391−401.
Walter et al. (2003) J Immunol., Nov 15;171(10):4974−8.
Knies et al. An optimized single chain TCR scaffoldrelying on the assembly with the native CD3−complex prevents residual mispairing with endogenousTCRs in human T−cells. Oncotarget. 2016 Apr 19; 7(16):21199〜21221.
ThomasHoffmann et al. Quantitative Analysis of the Association Angle between T−cell ReceptorVα/Vβ Domains Reveals Important Features for Epitope Recognition. PLOS, July17, 2015, http://dx.doi.org/10.1371/journal.pcbi.1004244
Claims (15)
- 非修飾鎖のIMGT番号付けによる44位のアミノ酸が、修飾α鎖またはβ鎖と望まれないαまたはβ鎖との対合を減少させる、別の適切なアミノ酸で置換されている、抗原−MHC複合体に結合する能力を維持する、修飾T細胞受容体(TCR)α鎖もしくはβ鎖、またはその断片もしくは誘導体。
- 前記望まれないα鎖またはβ鎖が修飾されていない、請求項に記載の1修飾T細胞受容体(TCR)α鎖またはβ鎖。
- 前記可変ドメイン中の44位の前記アミノ酸が、アミノ酸Q、R、D、E、K、L、W、およびVからなる群から選択されるアミノ酸によって置換されている、請求項1または2に記載の修飾T細胞受容体(TCR)α鎖またはβ鎖。
- 前記修飾α鎖が、配列番号1または3と少なくとも95%の配列同一性を有する配列のフレームワーク領域を少なくとも含んでなる可変ドメイン配列を有し、および/または前記修飾β鎖が、配列番号2または4と少なくとも95%の配列同一性を有する配列のフレームワーク領域を含んでなる可変ドメイン域配列を有する、請求項1〜3のいずれか一項に記載の修飾T細胞受容体(TCR)α鎖またはβ鎖。
- 前記TCRが抗原−MHC複合体と結合する能力を維持する、請求項1〜4のいずれか一項に記載の修飾α鎖および/または修飾β鎖、またはその断片もしくは誘導体を含んでなる、組換えT細胞受容体(TCR)ヘテロ二量体。
- 前記αおよび/またはβ鎖の前記修飾が、Q、R、D、E、K、L、W、およびVからなる群から選択されるアミノ酸による44位の置換から選択される、請求項5に記載の組換えT細胞受容体(TCR)ヘテロ二量体。
- 前記α鎖およびβ鎖の前記修飾が、αQ44D/βQ44R;αQ44R/βQ44D;αQ44E/βQ44K;αQ44K/βQ44E;αQ44D/βQ44K;αQ44K/βQ44D;αQ44E/βQ44R;αQ44R/βQ44E;αQ44L/βQ44W;αQ44W/βQ44L;αQ44V/βQ44W;αQ44W/βQ44V;αW44D/βQ44R;αW44R/βQ44D;αW44E/βQ44K;αW44K/βQ44E;αW44D/βQ44K;αW44K/βQ44D;αW44E/βQ44R;αW44R/βQ44E;αW44L/βQ44W;αW44/βQ44L;αW44V/βQ44W;αW44/βQ44V;αH44D/βQ44R;αH44R/βQ44D;αH44E/βQ44K;αH44K/βQ44E;αH44D/βQ44K;αH44K/βQ44D;αH44E/βQ44R;αH44R/βQ44E;αH44L/βQ44W;αH44W/βQ44L;αH44V/βQ44W;αH44W/βQ44V;αK44D/βQ44R;αK44R/βQ44D;αK44E/βQ44K;αK44/βQ44E;αK44D/βQ44K;αK44/βQ44D;αK44E/βQ44R;αK44R/βQ44E;αK44L/βQ44W;αK44W/βQ44L;αK44V/βQ44W;αK44W/βQ44V;αE44D/βQ44R;αE44R/βQ44D;αE44/βQ44K;αE44K/βQ44E;αE44D/βQ44K;αE44K/βQ44D;αE44/βQ44R;αE44R/βQ44E;αE44L/βQ44W;αE44W/βQ44L;αE44V/βQ44W;αE44W/βQ44V;αQ44D/βR44;αQ44R/βR44D;αQ44E/βR44K;αQ44K/βR44E;αQ44D/βR44K;αQ44K/βR44D;αQ44E/βR44;αQ44R/βR44E;αQ44L/βR44W;αQ44W/βR44L;αQ44V/βR44W;αQ44W/βR44V;αW44D/βR44;αW44R/βR44D;αW44E/βR44K;αW44K/βR44E;αW44D/βR44K;αW44K/βR44D;αW44E/βR44;αW44R/βR44E;αW44L/βR44W;αW44/βR44L;αW44V/βR44W;αW44/βR44V;αH44D/βR44;αH44R/βR44D;αH44E/βR44K;αH44K/βR44E;αH44D/βR44K;αH44K/βR44D;αH44E/βR44;αH44R/βR44E;αH44L/βR44W;αH44W/βR44L;αH44V/βR44W;αH44W/βR44V;αK44D/βR44;αK44R/βR44D;αK44E/βR44K;αK44/βR44E;αK44D/βR44K;αK44/βR44D;αK44E/βR44;αK44R/βR44E;αK44L/βR44W;αK44W/βR44L;αK44V/βR44W;αK44W/βR44V;αE44D/βR44;αE44R/βR44D;αE44/βR44K;αE44K/βR44E;αE44D/βR44K;αE44K/βR44D;αE44R/βR44E;αE44L/βR44W;αE44W/βR44L;αE44V/βR44W;およびαE44W/βR44Vからなる群の置換対から選択され、好ましくはα44D/β44R;α44R/β44D;α44E/β44K;α44K/β44E;α44D/β44K;α44K/β44D;α44E/β44R;およびα44R/β44Eからなる群から選択される、請求項5または6に記載の組換えT細胞受容体(TCR)ヘテロ二量体。
- 前記TCRの前記α鎖が、配列番号1または3と少なくとも95%の配列同一性を有する配列のフレームワーク領域を少なくとも含んでなる可変ドメイン配列を有し、および/または前記TCRの前記β鎖が、配列番号2または4と少なくとも95%の配列同一性を有する配列のフレームワーク領域を含んでなる可変ドメイン配列を有する、請求項5〜7のいずれか一項に記載の組換えT細胞受容体(TCR)ヘテロ二量体。
- 請求項1〜4のいずれか一項に記載の修飾T細胞受容体(TCR)α鎖またはβ鎖、および/または請求項5〜8のいずれか一項に記載の組換えT細胞受容体(TCR)ヘテロ二量体をコ−ドする核酸分子。
- 請求項9に記載の核酸分子の少なくとも1つを含んでなる、プラスミドまたは発現ベクタ−。
- 請求項9に記載の1つまたは複数の核酸分子、または請求項10に記載のプラスミドもしくは発現ベクタ−で、対象補助から得られたT細胞を形質導入または形質移入するステップを含んでなる、修飾T細胞を調製する方法。
- 請求項11に従って生成される、修飾T細胞。
- それを必要とする対象の自己由来T細胞療法で使用するための、請求項12に記載の修飾T細胞。
- 前記それを必要とする対象に、前記修飾T細胞を含んでなる製剤を投与するステップを含んでなる、新生物疾患、炎症性疾患、感染性疾患もしくは自己免疫疾患に罹患している、またはそれらを発症するリスクがある、および/またはそれらであると診断された、治療を必要とする対象の治療で使用するための請求項12に記載の修飾T細胞。
- 請求項5〜8のいずれか一項に記載の組換えT細胞受容体(TCR)ヘテロ二量体であって、前記TCRがMHC複合体によって提示される抗原に特異的に結合し、前記抗原が腫瘍関連抗原(TAA)のエピト−プから選択される、組換えT細胞受容体(TCR)ヘテロ二量体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023010833A JP2023052688A (ja) | 2016-12-08 | 2023-01-27 | 対合が改善されたt細胞受容体t細胞 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662497895P | 2016-12-08 | 2016-12-08 | |
US62/497,895 | 2016-12-08 | ||
DE102016123893.7A DE102016123893A1 (de) | 2016-12-08 | 2016-12-08 | T-Zellrezeptoren mit verbesserter Bindung |
DE102016123893.7 | 2016-12-08 | ||
PCT/EP2017/081745 WO2018104407A1 (en) | 2016-12-08 | 2017-12-06 | T cell receptors with improved pairing |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023010833A Division JP2023052688A (ja) | 2016-12-08 | 2023-01-27 | 対合が改善されたt細胞受容体t細胞 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2020500525A true JP2020500525A (ja) | 2020-01-16 |
JP2020500525A5 JP2020500525A5 (ja) | 2020-05-07 |
JP7346294B2 JP7346294B2 (ja) | 2023-09-19 |
Family
ID=62201182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019529260A Active JP7346294B2 (ja) | 2016-12-08 | 2017-12-06 | 対合が改善されたt細胞受容体t細胞 |
Country Status (14)
Country | Link |
---|---|
US (2) | US11072645B2 (ja) |
EP (1) | EP3551653B1 (ja) |
JP (1) | JP7346294B2 (ja) |
CN (1) | CN110099923A (ja) |
AU (1) | AU2017371260C1 (ja) |
BR (1) | BR112019010803A2 (ja) |
CA (1) | CA3045230A1 (ja) |
CR (1) | CR20190280A (ja) |
DE (1) | DE102016123893A1 (ja) |
MA (1) | MA47359A (ja) |
MX (1) | MX2019006726A (ja) |
PE (1) | PE20191150A1 (ja) |
TW (1) | TWI710572B (ja) |
WO (1) | WO2018104407A1 (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
DE102017106305A1 (de) | 2017-03-23 | 2018-09-27 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten |
DE102017125888A1 (de) | 2017-11-06 | 2019-05-23 | Immatics Biotechnologies Gmbh | Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie |
EP4219543A1 (en) | 2017-11-06 | 2023-08-02 | Immatics Biotechnologies GmbH | Novel engineered t cell receptors and immune therapy using the same |
DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
JP2022534716A (ja) | 2019-05-27 | 2022-08-03 | イマティクス ユーエス,アイエヌシー. | ウイルスベクターおよびその養子細胞療法における使用 |
DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
EP4090365A1 (en) | 2020-01-15 | 2022-11-23 | Immatics Biotechnologies GmbH | Antigen binding proteins specifically binding prame |
JP2023515131A (ja) | 2020-02-24 | 2023-04-12 | イマティクス ユーエス,アイエヌシー. | がんおよび関連する悪性腫瘍の治療のためにt細胞を増殖させる方法 |
DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
TW202227616A (zh) | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | 分離cd8+選擇t細胞的方法 |
EP4271481A2 (en) | 2020-12-31 | 2023-11-08 | Immatics US, Inc. | Cd8 polypeptides, compositions, and methods of using thereof |
WO2022184805A1 (en) | 2021-03-03 | 2022-09-09 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein |
AU2022270361A1 (en) | 2021-05-05 | 2023-11-16 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
AU2022318257A1 (en) | 2021-07-27 | 2024-02-08 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding ct45 |
WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
US20230142468A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
EP4198052A1 (en) | 2021-12-15 | 2023-06-21 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Peptides and antigen binding proteins for use in immunotherapy against fibrolamellar hepatocellular carcinoma (fl-hcc) and other cancers |
US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
WO2023212697A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2244744A1 (en) * | 1996-02-01 | 1997-08-07 | University Of Florida | Lyst1 and lyst2 gene compositions and methods of use |
DE10225139A1 (de) | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
DE10225144A1 (de) | 2002-05-29 | 2003-12-18 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
DE10313819A1 (de) | 2003-03-24 | 2004-10-07 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
EP1714157A2 (en) | 2004-01-28 | 2006-10-25 | Immatics Biotechnologies GmbH | Method for identifying and quantifying of tumour-associated peptides |
DE102004026135A1 (de) | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
ATE512160T1 (de) | 2005-04-26 | 2011-06-15 | Immatics Biotechnologies Gmbh | T-cell-epitope aus dem unreifen lamininrezeptorprotein (oncofoetal antigen) und deren medizinische verwendungen |
PT1806358E (pt) | 2005-09-05 | 2010-05-28 | Immatics Biotechnologies Gmbh | Peptídeos associados a tumor ligando promiscuamente às moléculas do antigénio de leucócitos humanos (hla) da classe ii |
ATE440107T1 (de) | 2005-09-05 | 2009-09-15 | Immatics Biotechnologies Gmbh | Tumorassoziierte peptide, die hla klasse i oder ii-moleküle binden, und anti-tumor impfstoffe |
SI2567707T1 (sl) | 2007-07-27 | 2017-01-31 | Immatics Biotechnologies Gmbh | Sestava s tumorjem povezanih peptidov in zadevnih cepiv proti raku |
PT2660248E (pt) | 2007-07-27 | 2015-10-12 | Immatics Biotechnologies Gmbh | Nova imunoterapia para tumores neuronais e cerebrais |
CA2694805C (en) | 2007-07-27 | 2014-09-09 | Immatics Biotechnologies Gmbh | Immunogenic epitopes of tumour-associated antigens |
DK2288700T3 (en) * | 2008-05-09 | 2017-05-22 | Agency Science Tech & Res | HBV EPITOP-REACTIVE EXOGEN T-CELL RECEPTOR (TCR) AND APPLICATIONS THEREOF |
NO2119726T3 (ja) | 2008-05-14 | 2015-05-23 | ||
PT2172211E (pt) | 2008-10-01 | 2015-03-09 | Immatics Biotechnologies Gmbh | Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer |
GB0917094D0 (en) * | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
US9023802B2 (en) | 2009-12-14 | 2015-05-05 | Immatics Biotechnologies Gmbh | HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
GB201004575D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
GB201019331D0 (en) | 2010-03-19 | 2010-12-29 | Immatics Biotechnologies Gmbh | Methods for the diagnosis and treatment of cancer based on AVL9 |
GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
GB201009222D0 (en) | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
GB201015765D0 (en) | 2010-09-21 | 2010-10-27 | Immatics Biotechnologies Gmbh | Use of myeloid cell biomarkers for the diagnosis of cancer |
GB201021289D0 (en) | 2010-12-15 | 2011-01-26 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
KR20130126671A (ko) | 2010-12-14 | 2013-11-20 | 이매틱스 바이오테크놀로지스 게엠베하 | 전립선 관련 항원 분자로부터 유래된 hla 결합 펩티드 및 이의 사용방법 |
GB2508414A (en) | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
JP6346266B2 (ja) | 2013-03-21 | 2018-06-20 | サンガモ セラピューティクス, インコーポレイテッド | 操作されたジンクフィンガータンパク質ヌクレアーゼを使用するt細胞受容体遺伝子の標的化された破壊 |
TWI777194B (zh) | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物(一) |
PE20150600A1 (es) | 2013-10-15 | 2015-06-03 | Vignolo Carlos Alberto Ibanez | CICLO - BICICLETA HIBRIDA MOTORIZADA 2 x 2 |
GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
GB201408255D0 (en) | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
GB201411037D0 (en) | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
GB2528124A (en) | 2014-07-11 | 2016-01-13 | Nec Corp | Communication system |
TWI617841B (zh) | 2014-10-22 | 2018-03-11 | 英特爾股份有限公司 | 用於光學系統的防雲紋圖樣擴散器 |
WO2016064317A1 (en) | 2014-10-24 | 2016-04-28 | Telefonaktiebolaget L M Ericsson (Publ) | Method and arrangement for csi-rs transmission |
CN104460328B (zh) | 2014-10-29 | 2019-05-10 | 小米科技有限责任公司 | 基于设定场景模式的智能设备控制方法和装置 |
DE102014016105A1 (de) | 2014-10-30 | 2016-05-04 | Head Technology Gmbh | Superelastische Schlägersaite |
TWI752410B (zh) | 2014-10-30 | 2022-01-11 | 美商艾科詹瑟斯有限公司 | 由混合固體廢棄物形成之固體燃料組合物 |
MA40904A (fr) | 2014-11-03 | 2017-09-12 | Hygeia Tech Inc | Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie |
EP3215164A1 (en) | 2014-11-03 | 2017-09-13 | Immures S.r.l. | T cell receptors |
WO2016073587A1 (en) | 2014-11-04 | 2016-05-12 | Spinal Stabilization Technologies Llc | Percutaneous implantable nuclear prosthesis |
CA2967241C (en) | 2014-11-17 | 2023-01-31 | Mitrassist Medical Ltd. | Heart valve prosthesis |
US10207318B2 (en) | 2014-11-20 | 2019-02-19 | Abb Schweiz Ag | Electromagnetic brake system and method of controlling molten metal flow in a metal-making process |
DE102014223758A1 (de) | 2014-11-20 | 2016-05-25 | Windmöller & Hölscher Kg | Kontaktwalze |
GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
GB201423361D0 (en) | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
EP3067366A1 (en) | 2015-03-13 | 2016-09-14 | Max-Delbrück-Centrum Für Molekulare Medizin | Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1 |
GB201504502D0 (en) | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
GB201510771D0 (en) | 2015-06-19 | 2015-08-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer |
GB201511191D0 (en) | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
GB201511792D0 (en) | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
MY189596A (en) | 2015-07-15 | 2022-02-18 | Immatics Biotechnologies Gmbh | A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
GB201515321D0 (en) | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
JP6862435B2 (ja) | 2015-10-09 | 2021-04-21 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 抗wt1/hla特異的抗体 |
GB201521746D0 (en) | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
GB201521894D0 (en) | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
GB201522667D0 (en) | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
-
2016
- 2016-12-08 DE DE102016123893.7A patent/DE102016123893A1/de active Pending
-
2017
- 2017-12-06 WO PCT/EP2017/081745 patent/WO2018104407A1/en unknown
- 2017-12-06 US US15/833,778 patent/US11072645B2/en active Active
- 2017-12-06 EP EP17825761.4A patent/EP3551653B1/en active Active
- 2017-12-06 PE PE2019001163A patent/PE20191150A1/es unknown
- 2017-12-06 BR BR112019010803A patent/BR112019010803A2/pt unknown
- 2017-12-06 MA MA047359A patent/MA47359A/fr unknown
- 2017-12-06 AU AU2017371260A patent/AU2017371260C1/en active Active
- 2017-12-06 JP JP2019529260A patent/JP7346294B2/ja active Active
- 2017-12-06 CR CR20190280A patent/CR20190280A/es unknown
- 2017-12-06 CN CN201780075297.XA patent/CN110099923A/zh active Pending
- 2017-12-06 MX MX2019006726A patent/MX2019006726A/es unknown
- 2017-12-06 CA CA3045230A patent/CA3045230A1/en active Pending
- 2017-12-08 TW TW106143062A patent/TWI710572B/zh active
-
2021
- 2021-06-22 US US17/354,555 patent/US20210380659A1/en active Pending
Non-Patent Citations (2)
Title |
---|
"SUBNAME: FULL=UNCHARACTERIZED PROTEIN {ECO:0000313|ENSEMBL:ENSCJAP00000012641}", JPN6021015041, 2016, ISSN: 0005011719 * |
"T-CELL RECEPTOR ALPHA CHAIN, PARTIAL [CALLITHRIX JACCHUS]", JPN6021015040, 2016, ISSN: 0005011718 * |
Also Published As
Publication number | Publication date |
---|---|
BR112019010803A2 (pt) | 2019-10-01 |
US20210380659A1 (en) | 2021-12-09 |
CR20190280A (es) | 2019-10-07 |
EP3551653A1 (en) | 2019-10-16 |
CN110099923A (zh) | 2019-08-06 |
US11072645B2 (en) | 2021-07-27 |
MX2019006726A (es) | 2019-09-04 |
AU2017371260C1 (en) | 2020-11-19 |
JP7346294B2 (ja) | 2023-09-19 |
WO2018104407A1 (en) | 2018-06-14 |
US20180162922A1 (en) | 2018-06-14 |
DE102016123893A1 (de) | 2018-06-14 |
EP3551653B1 (en) | 2023-11-01 |
PE20191150A1 (es) | 2019-09-02 |
AU2017371260A1 (en) | 2019-06-20 |
CA3045230A1 (en) | 2018-06-14 |
AU2017371260B2 (en) | 2020-07-23 |
MA47359A (fr) | 2019-12-04 |
TWI710572B (zh) | 2020-11-21 |
TW201827460A (zh) | 2018-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7346294B2 (ja) | 対合が改善されたt細胞受容体t細胞 | |
JP6615612B2 (ja) | 新規腫瘍特異的t細胞レセプター | |
JP7452880B2 (ja) | Ssx2抗原を識別するt細胞受容体 | |
WO2021068938A1 (zh) | 一种识别kras突变的t细胞受体及其编码序列 | |
WO2020029774A1 (zh) | 一种嵌合t细胞受体star及其应用 | |
Thomas et al. | Molecular immunology lessons from therapeutic T‐cell receptor gene transfer | |
Merhavi-Shoham et al. | Genetically modulating T-cell function to target cancer | |
JP2008504043A (ja) | 改変t細胞レセプターを発現する細胞 | |
JP7429455B2 (ja) | Afp抗原を識別するt細胞受容体 | |
US20190038730A1 (en) | Engineered cells & methods | |
JP2022546524A (ja) | 腫瘍ネオアンチゲンペプチドを標的とする免疫療法 | |
JP7429462B2 (ja) | Ssx2抗原の短いペプチドを識別するt細胞受容体 | |
US20220064256A1 (en) | Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies | |
WO2021022447A1 (zh) | 识别afp抗原短肽的t细胞受体 | |
WO2021170116A1 (zh) | 一种识别afp的t细胞受体 | |
TW202140539A (zh) | 一種辨識afp抗原短鏈胜肽的t細胞受體及其編碼序列 | |
JP2023052688A (ja) | 対合が改善されたt細胞受容体t細胞 | |
JP2023519727A (ja) | Cd3融合タンパク質およびその使用 | |
TW202140532A (zh) | 一種辨識afp的t細胞受體及其編碼序列 | |
WO2021035446A1 (zh) | 一种识别afp抗原短肽的t细胞受体及其编码序列 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200330 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200330 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210426 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210721 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210902 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211206 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220603 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220927 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230127 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20230127 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230202 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20230206 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20230227 |
|
RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20230302 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230303 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230314 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230613 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230616 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230808 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230906 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7346294 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |